ENvue Medical, Inc. (FEED)
NASDAQ: FEED · Real-Time Price · USD
1.010
-0.085 (-7.76%)
At close: May 18, 2026, 4:00 PM EDT
1.011
+0.001 (0.13%)
After-hours: May 18, 2026, 7:34 PM EDT

ENvue Medical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2.182.552.562.280.751.7
Revenue Growth (YoY)
-18.07%-0.19%12.05%203.59%-55.63%172.07%
Cost of Revenue
2.452.41.050.750.590.93
Gross Profit
-0.270.151.511.540.170.77
Selling, General & Admin
11.6210.134.184.794.96.16
Research & Development
1.71.760.910.190.280.29
Other Operating Expenses
-11.15----
Total Operating Expenses
13.3223.045.094.975.186.45
Operating Income
-13.59-22.89-3.58-3.44-5.01-5.68
Total Non-Operating Income (Expense)
-4.54-4.40.1-0.02-0.29-8.47
Pretax Income
-18.13-27.29-3.48-3.46-5.31-14.15
Provision for Income Taxes
-0.29-0.310.020.030.040.03
Net Income
-37.52-16.78-3.71-0-0-0.01
Net Income Attributable to Preferred Dividends
-17.36-2.21----
Net Income to Common
-37.52-16.78-3.71-0-0-0.01
Shares Outstanding (Basic)
110000
Shares Outstanding (Diluted)
110000
Shares Change (YoY)
1393.43%2229.20%2199.96%-12.84%4786.90%
EPS (Basic)
-28.82-26.69-137.30-17.40-0.00-13733.50
EPS (Diluted)
-28.82-26.69-137.30-17.40-0.00-13733.50
Shares Outstanding
3.71.10.040.190.010.01
Free Cash Flow
-12.41-9.43-2.52-3.6-7.04-4.37
Free Cash Flow Per Share
-8.66-15.01-93.35-3070.88-5998.56-4202.79
Gross Margin
-12.43%5.99%58.95%67.32%22.21%45.43%
Operating Margin
-623.29%-896.55%-140.03%-150.50%-666.49%-335.28%
Profit Margin
-923.20%-712.30%-144.84%-162.55%-724.47%-842.60%
FCF Margin
-569.14%-369.45%-98.48%-157.82%-935.90%-257.82%
EBITDA
-12.5-21.99-3.58-3.44-5.01-5.68
EBITDA Margin
-573.04%-861.42%-139.99%-150.46%-666.36%-335.16%
EBIT
-13.59-22.89-3.58-3.44-5.01-5.68
EBIT Margin
-623.29%-896.55%-140.03%-150.50%-666.49%-335.28%
Effective Tax Rate
1.59%1.13%-0.55%-0.84%-0.66%-0.23%
Updated May 18, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.